Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report

J Med Case Rep. 2017 Feb 2;11(1):29. doi: 10.1186/s13256-017-1202-x.

Abstract

Background: We report a case of a patient with recurrent severe hypoglycemia after initiating the drug rasagiline (Azilect) for Parkinson disease.

Case presentation: A 25-year-old Emirati woman who had been diagnosed with Parkinson disease due to a genetic mutation since the age of 18 years presented to our hospital. She had been treated with a rotigotine patch 2 mg per day along with carbidopa + levodopa + entacapone 25 mg/100 mg/200 mg (Stalevo) over these years. Recently, her Stalevo had been changed to rasagiline (a monoamine oxidase B inhibitor). Soon after this change, she started experiencing recurrent documented severe hypoglycemia requiring hospitalization. Her hypoglycemic symptoms completely disappeared after 5-7 days of drug withdrawal. Despite detailed evaluation, no other causal relationship was documented except for rasagiline.

Conclusions: To the best of our knowledge, this case report documents an unknown association between rasagiline and hypoglycemia.

Keywords: Case report; Diabetes; Hypoglycemia; MAO inhibitor; Parkinson disease; Rasagiline; SSRI.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Humans
  • Hypoglycemia / chemically induced*
  • Indans / adverse effects*
  • Monoamine Oxidase Inhibitors / adverse effects*
  • Parkinson Disease / drug therapy*

Substances

  • Indans
  • Monoamine Oxidase Inhibitors
  • rasagiline